Dexetimide: Clinical Trials

55 trials of Dexetimide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed, 9 unknown, 4 withdrawn, 3 terminated. 24 Phase 4, 10 Not applicable, 9 Phase 2, 8 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 424Completed 17, Withdrawn 3, Recruiting 2, Unknown 2
Not applicable10Completed 8, Unknown 2
Phase 29Completed 6, Unknown 2, Terminated 1
Phase 38Completed 4, Terminated 2, Unknown 1, Withdrawn 1
Phase 13Completed 1, Terminated 1, Unknown 1

Follow Dexetimide: new trials by email Literature Review of Dexetimide trials Research Report on Dexetimide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Escitalopram, Brexpiprazole - Major Depressive Disorder
Phase 4RecruitingNova Scotia Health Authority4002023-01-202026-06-11
Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline, Cipralex (escitalopram) - Major Depressive Disorder (MDD)
Phase 4RecruitingMedical University of Vienna1202022-12-012024-11-05
Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants
either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe - Breast Feeding
CompletedThe Hospital for Sick Children392022-03-092024-04-10
Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
Escitalopram, Brexpiprazole - Major Depressive Disorder
Phase 3CompletedUniversity Health Network, Toronto12019-12-232023-03-02
Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety
Gaze Contingent Music Reward Therapy, Escitalopram, Waitlist - Social Anxiety Disorder
Not applicableCompletedTel Aviv University1052018-07-202022-02-01
PF-04995274 and Emotional Processing in Un-medicated Depression
PF-04995274, Citalopram, Placebo Oral Tablet - Depression, Unipolar
Phase 1CompletedUniversity of Oxford902018-05-162022-11-03
Cortical Ischemic Stroke and Serotonin
Serotonin Uptake Inhibitors, Placebo - Stroke
Phase 2UnknownInsel Gruppe AG, University Hospital Bern902016-08-012020-03-06
The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
Escitalopram, placebo - GBM, Depression
Phase 2 / Phase 3UnknownTel-Aviv Sourasky Medical Center1002015-12-012015-12-07
Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)
PET/MR [11C]DASB, Citalopram, Escitalopram (Mirtazapine/Duloxetine/Venlafaxine) - Major Depressive Disorder
Phase 4UnknownMedical University of Vienna802015-05-012019-09-03
Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
Fluoxetine, Sertraline, Paroxetine - Obsessive-Compulsive Disorder, Anxiety Disorders
Phase 4CompletedShanghai Mental Health Center782014-01-012022-09-09
The Efficacy of Citalopram Treatment in Acute Stroke
Citalopram, Placebo - Stroke, Ischemic
Phase 2CompletedUniversity of Aarhus6422013-09-012017-02-24
The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS
Cipralex, Placebo - Polycystic Ovary Syndrome
Phase 4CompletedOdense University Hospital422013-06-012016-05-09
The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives
Vilazodone, Citalopram - Major Depressive Disorder, Anxiety
Phase 4WithdrawnMassachusetts General Hospital2013-04-012016-11-08
Canadian Biomarker Integration Network for Depression Study
escitalopram, aripiprazole - Major Depressive Disorder
Phase 3CompletedUniversity Health Network, Toronto2112012-04-232018-05-11
Antidepressants and Bone Mineral Density
sertraline, citalopram, venlafaxine - Bone Mineral Density Quantitative Trait Locus 7
Phase 3CompletedGuiyang Medical University2032012-03-012014-07-01
Serotonergic System and Violent Video Games
cipralex - Healthy Volunteers
Not applicableCompletedRWTH Aachen University472012-02-012015-09-29
Analgesic Effect of Escitalopram in Total Knee Arthroplasty (TKA)
Escitalopram, Placebo - Postoperative Pain
Phase 4CompletedHvidovre University Hospital1202011-09-012013-06-05
Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response
Escitalopram - Depression
Phase 4CompletedMedical University of Vienna262011-08-012016-10-31
Exploring Biomarkers for Depression
Escitalopram, Healthy Control - Major Depressive Disorder
CompletedWyss Institute at Harvard University512011-08-012018-05-01
Predictors of Antidepressant Response
Placebo, identified as placebo to participants, Celexa or other antidepressant as clinically indicated, Placebo, identifed to participants as "Active medication" - Depression
Phase 4CompletedUniversity of Michigan442011-01-012017-12-05

Showing 20 of 55. Sign in to see all of them.

Conditions studied

Depressive Disorder, Major (17)  ·  Depression (16)  ·  Anxiety Disorders (5)  ·  Depressive Disorder (4)  ·  Obsessive-Compulsive Disorder (4)  ·  Phobia, Social (4)  ·  Stroke (3)  ·  Generalized Anxiety Disorder (2)  ·  Psychotic Disorders (2)  ·  Alcoholism (1)  ·  Alzheimer Disease (1)  ·  Angina, Unstable (1)  ·  Anxiety, Separation (1)  ·  Bipolar Disorder (1)  ·  Breast Feeding (1)

Sponsors

H. Lundbeck A/S (3)  ·  Medical University of Vienna (3)  ·  Abarbanel Mental Health Center (2)  ·  Eli Lilly and Company (2)  ·  Hadassah Medical Organization (2)  ·  Massachusetts General Hospital (2)  ·  Tel-Aviv Sourasky Medical Center (2)  ·  University Health Network, Toronto (2)  ·  University of Aarhus (2)  ·  University of Copenhagen (2)  ·  University of Ottawa (2)  ·  Centre for Addiction and Mental Health (1)  ·  Chonnam National University Hospital (1)  ·  Espace Hogan (1)  ·  Finnish Institute for Health and Welfare (1)

Countries

Canada (12)  ·  United States (9)  ·  Denmark (7)  ·  Israel (7)  ·  Austria (3)  ·  Switzerland (3)  ·  Germany (2)  ·  Romania (2)  ·  Russia (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Brazil (1)  ·  China (1)  ·  Estonia (1)  ·  Finland (1)

Top investigators

A. Daigneault, Dr. (1)  ·  A. Ravindran, Dr. (1)  ·  A. Schaffer, Dr. (1)  ·  A.V. Mysore, Dr. (1)  ·  Alyn H Morice, Professor (1)  ·  Andrew A. Nierenberg, M.D. (1)  ·  Andrew Nierenberg, MD (1)  ·  Aviv M Weinstein, Ph.D (1)  ·  B. Frey, Dr. (1)  ·  Birte Glenthoj, MD, DMSc. (1)  ·  Boris Modrau, M.D. (1)

Results publications

PMID 10534584, PMID 11110112, PMID 16009352, PMID 17559755, PMID 18348597, PMID 18834506, PMID 19578654, PMID 19671139, PMID 21034680, PMID 21738622, PMID 21811192, PMID 21907540, PMID 22393376, PMID 22722513, PMID 22841131, PMID 23948637, PMID 25375836, PMID 25412614, PMID 25581916, PMID 26313133, PMID 26421634, PMID 26709390, PMID 30043065, PMID 30079814, PMID 30355209, PMID 30840787, PMID 31471185, PMID 31907104, PMID 32241310, PMID 32349119, PMID 32558407, PMID 32836109, PMID 33032615, PMID 33296696, PMID 33520402, PMID 33667309, PMID 33683582, PMID 33814546, PMID 33860922, PMID 34008342, PMID 34229186, PMID 34416758, PMID 35023065, PMID 35459929, PMID 35546043, PMID 36945823, PMID 36997260, PMID 37530824, PMID 37796764, PMID 37967350

NIH funding

2004 (1), 2016 (1), 2019 (1), R01MH061394 (1), R01MH061757 (1), R01MH061758 (1), R01MH084900 (1), R34MH070753 (1)